Please login to the form below

Not currently logged in
Email:
Password:

Valeant makes $312m OraPharma acquisition

Takes control of gum disease treatment Arestin and Listerine family

Arestin - Valeant OraPhama

Valeant Pharmaceuticals has continued its run of acquisitions with the purchase of oral health company OraPharma.

Canadian pharma firm Valeant will make an initial payment of $312m to OraPharma's owners Water Street Healthcare Partners, with the cost potentially increasing by $114m depending on certain milestones.

The transaction, which is expected to close by the end of June 2012, will see Valeant take control of OraPharma's lead product, Arestin (minocycline hydrochloride) – an antiobiotic to treat gum disease, and the Listerine family of mouthwashes, which OraPharma markets in partnership with Johnson & Johnson (J&J).

According to Valeant, OraPharma's net revenue for the previous 12 months was $95m, with business growing at a single digit rate.

The oral health market is new territory for Valeant, although chair and CEO J Michael Pearson was confident of the acquisition's potential based on experience in related areas.

He said: "We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese.

“We believe the OraPharma business is a new growth platform from which to build additional opportunities in the future."

Valeant has expanded into several therapy areas and geographies in recent months, paying $27m for footcare specialist Pedinol Pharmacal in April, 2012 and acquiring Russian OTC company Natur Produkt for $180, in a deal that gave Valeant control of several cough and cold remedies.

Other moves into Russia for Valeant include the acquisition of a portfolio of generics drugs from Austria-based Gerot Lannach and which are sold in Russia.

18th June 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics